Lenalidomide Pregnancy Prevention Programme

Women of Non-Childbearing Potential

Risk Awareness Form

Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme via www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to the relevant MAH.

Risk Awareness Form for counselling the patient to ensure the patient is fully informed about the safe use of lenalidomide

Introduction

This Risk Awareness Form is to assist you with counselling a patient before they commence lenalidomide treatment in order to ensure the medicine is used safely and correctly. A form must be completed for each woman of non-childbearing potential prior to the initiation of their lenalidomide treatment. This form must be completed by a physician with expertise in managing immunomodulatory drugs.

The purpose of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse drug reactions associated with the use of lenalidomide. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of lenalidomide.

The form should be retained with the patient's medical records, and a photocopy provided to them. This form is not a contract and does not absolve anybody from his/her responsibilities regarding the safe use of the product and prevention of foetal exposure

Warning: Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Lenalidomide induced in monkeys malformations similar to those described with thalidomide. If lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected. The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.

If lenalidomide is taken during pregnancy it is expected to cause severe birth defects or death to an unborn baby.

Patient Details

Patient's First Name:

Patient's Last Name:

Date of Birth:	DD	MM	YYYY

Counselling Date:	DD	MM	YYYY

Date of preparation of text: April 2025
Approved by MHRA: May 2025
PATH-LEN-009_v.2.0

Pathfinder
Risk Management Platform

Did you inform your patient:	Woman of Non-Childbearing Potential
1) To not share the medicinal product with any other person?	Tick
2) That they should not donate blood during treatment (including during dose interruptions) and for at least 7 days following discontinuation of lenalidomide?	Tick
3) That they should return the unused capsules to the pharmacist at the end of treatment ?	Tick

Prescriber Confirmation

I have fully explained to the patient named above the nature, purpose and risks of the treatment associated with lenalidomide especially the risks to women of childbearing potential.
I will comply with all my obligations and responsibilities as the prescriber of lenalidomide.

Prescriber's First Name:

Prescriber's Last Name:

Prescriber's Signature:		Date:	DD	MM	YYYY

Patient: please read thoroughly and initial the adjacent box if you agree with the statement

I understand that severe birth defects are expected to occur with the use of lenalidomide. I have been warned by my prescriber that any unborn baby has a high risk of birth defects and could even die if a woman is pregnant or becomes pregnant while taking lenalidomide	Patient Initials
I have read the lenalidomide Patient Information Guide and understand the contents, including the information about other possible important health problems (side effects) associated with the use of lenalidomide.	Patient Initials
I understand that lenalidomide will be prescribed ONLY for me. I must not share it with ANYONE	Patient Initials
I know that I cannot donate blood while taking lenalidomide (including dose interruptions) and for at least 7 days after stopping treatment.	Patient Initials
I understand that I must return any unused lenalidomide capsules to my pharmacy at the end of my treatment.	Patient Initials
I have been informed about the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with lenalidomide	Patient Initials

Patient Confirmation

I confirm that I understand and will comply with the requirements of the lenalidomide Pregnancy Prevention Programme, and I agree that my prescriber can initiate my treatment with lenalidomide.

I understand that in order to receive lenalidomide as part of the medical care and treatment that I am receiving, my personal data will be collected and processed by my treating healthcare institution and the relevant Marketing Authorisation Holder (i.e. the supplier of lenalidomide) and their processors,

HealthBeacon plc and Pharmacare Group Ltd. I further understand that my personal data will be processed and retained in accordance with applicable laws and regulations, as described in the relevant party's privacy policy, which can be found on their website.

Patient Signature:		**Date:**	DD	MM	YYYY

Statement of the interpreter (where appropriate)

I have interpreted the information above to the patient/parent to the best of my ability and in a way in which I believe she/he/they can understand. She/he/they agree to follow the necessary precautions to prevent an unborn child being exposed to lenalidomide.

Interpreter Signature:		**Name:** (print)		**Date:**	DD	MM	YYYY